For example, aberrant p15 (CDKN2B) promoter hypermethylation has been found frequently [reportedly up to 80% of patients (21)] in myeloid dysplasia/neoplasm and AML (22, , –25), but whether p15 hypermethylation impacts cell biology or contributes to the development of disease is unknown due to a lack of functional experiments. Here, CDKN2B is linked to acute myeloid leukemia.